Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PRTN3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PRTN3 ECD-Fc / S195A Protease-Inactive Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View PRTN3 Products |
| Gene Delivery | PRTN3 Promise-ORF / Lentivirus Full-length ORF for stable cell lines to analyze membrane-bound PRTN3 (mPR3). |
View PRTN3 Products |
| Benchmark Ab | Anti-PRTN3 Recombinant Antibody Recombinant positive control derived from clinical-stage benchmark sequences. |
View PRTN3 Products |
| Validator | PRTN3 siRNA Set For target knockdown and specificity validation in primary neutrophils or cell lines. |
View PRTN3 Products |
| Related Target A | ELANE (Neutrophil Elastase) Highly homologous serine protease; critical for off-target selectivity and counter-screening panels. |
View ELANE Products |
| Related Target B | MPO (Myeloperoxidase) Co-released with PRTN3 during neutrophil activation; key biomarker and therapeutic target in ANCA-associated vasculitis. |
View MPO Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Proteolytic Autolysis during SPR/ELISA assays | S195A active-site mutant recombinant protein preserves native conformation while eliminating self-degradation. |
| Subfamily protease cross-reactivity (ELANE, Cathepsin G) | High-purity homologous panel proteins strictly verified by mass spectrometry and sequence alignment. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live PRTN3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PRTN3 therapeutics is intensifying, with major players shifting focus from traditional systemic immunosuppression to targeted membrane-bound PRTN3 (mPR3) inhibitors and autoantibody-blocking biologics. As first-generation therapies reach the clinic, the next wave of R&D is targeting neutrophil-mediated chronic inflammatory conditions, such as Granulomatosis with Polyangiitis (GPA) and severe COPD, where selective inhibition without systemic toxicity is paramount.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | AstraZeneca, Roche | ANCA-Associated Vasculitis, COPD | Epitope mapping & conformational binding assays (Requires native glycosylation HEK293-expressed PRTN3). |
| Small Molecule Inhibitor | Insmed, Boehringer Ingelheim | Bronchiectasis, ARDS | Enzymatic activity & selectivity screening (Requires active wild-type vs. inactive mutant panels). |
| TCR-like Therapeutics | Academic Institutes, Biotech Startups | Acute Myeloid Leukemia (AML) | PR1/HLA-A2 complex presentation validation (Requires sequence-verified recombinant proteins and stable cell lines). |